Since so many TNF inhibitors, including biosimilars and biologic DMARDs with other mechanisms, are available worldwide, further effort should invested in identifying a strategy for appropriate selection of biologic DMARDs for elderly RA patients. The gene discussed is TNF; the disease is rheumatoid arthritis.